Evidence map›Paper›PMID 33562339›Full record

ReviewInternational journal of molecular sciences2021

Preventing Brain Injury in the Preterm Infant-Current Controversies and Potential Therapies.

Nathanael Yates, Alistair J Gunn, Laura Bennet, Simerdeep K Dhillon, Joanne O Davidson

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
22.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. [Risk factors associated with neurodevelopmental outcomes at 2-3 years of corrected age in extremely preterm infants].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Article
  6. Article
  7. Observational
  8. Review
  9. Review
  10. Perinatal Neuroprotection in Preterm Birth.Geburtshilfe und Frauenheilkunde · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Nathanael YatesThe Queensland Brain Institute, University of Queensland, St Lucia, QLD 4072, Australia.ORCID 0000-0003-2742-6952
Alistair J GunnThe Department of Physiology, University of Auckland, Auckland 1023, New Zealand.ORCID 0000-0003-0656-7035
Laura BennetThe Department of Physiology, University of Auckland, Auckland 1023, New Zealand.
Simerdeep K DhillonThe Department of Physiology, University of Auckland, Auckland 1023, New Zealand.
Joanne O DavidsonThe Department of Physiology, University of Auckland, Auckland 1023, New Zealand.
University of Auckland · NZThe University of Queensland · AU

Funding

The Health Research council of New Zealand 16/003The Health Research council of New Zealand 18/225
6 · The paper itself

Abstract

Preterm birth is associated with a high risk of morbidity and mortality including brain damage and cerebral palsy. The development of brain injury in the preterm infant may be influenced by many factors including perinatal asphyxia, infection/inflammation, chronic hypoxia and exposure to treatments such as mechanical ventilation and corticosteroids. There are currently very limited treatment options available. In clinical trials, magnesium sulfate has been associated with a small, significant reduction in the risk of cerebral palsy and gross motor dysfunction in early childhood but no effect on the combined outcome of death or disability, and longer-term follow up to date has not shown improved neurological outcomes in school-age children. Recombinant erythropoietin has shown neuroprotective potential in preclinical studies but two large randomized trials, in extremely preterm infants, of treatment started within 24 or 48 h of birth showed no effect on the risk of severe neurodevelopmental impairment or death at 2 years of age. Preclinical studies have highlighted a number of promising neuroprotective treatments, such as therapeutic hypothermia, melatonin, human amnion epithelial cells, umbilical cord blood and vitamin D supplementation, which may be useful at reducing brain damage in preterm infants. Moreover, refinements of clinical care of preterm infants have the potential to influence later neurological outcomes, including the administration of antenatal and postnatal corticosteroids and more accurate identification and targeted treatment of seizures.

Indexed as

Anti-Inflammatory AgentsBrain InjuriesHumansInfant, NewbornInfant, PrematureInfant, Premature, DiseasesAnti-Inflammatory Agentsanticonvulsantscorticosteroidserythropoietinhypothermianeuroprotectionpreterm asphyxiastem cells

Identifiers

PMID33562339
PMCPMC7915709
OpenAlexW3127135240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.